An Overview of the European Union's New Medicines Legislation: Implications for the Pharmaceutical Industry

ISSN： 1364-9027

Source： International Journal of Pharmaceutical Medicine, Vol.20, Iss.4, 2006-01, pp. : 251-261

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

EFPIA workshop: the 2001 review of European Union pharmaceutical legislation

By Donna E. Elena M.

International Journal of Pharmaceutical Medicine, Vol. 15, Iss. 3, 2001-06 ,pp. : 145-149

Adis International

Access to resources Recommend Favorite

Single European Currency and Monetary Union: Macroeconomic Implications for Pharmaceutical Spending

By Kanavos P.

PharmacoEconomics, Vol. 13, Iss. 1 Part 2, 1998-01 ,pp. : 9-20

Adis International

Access to resources Recommend Favorite

European Legislation on Herbal Medicines: A Look into the Future

By Calapai Gioacchino

Drug Safety, Vol. 31, Iss. 5, 2008-01 ,pp. : 428-431

Adis International

Access to resources Recommend Favorite

A record £3.5 billion was spent by the British pharmaceutical industry in 2003 in the search for new medicines

Inpharma, Vol. 1, Iss. 1432-1433, 2004-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

A record £3.5 billion was spent by the British pharmaceutical industry in 2003 in the search for new medicines

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 450, 2004-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite